Lung disease stem cell treatment drug ‘PNEUMOSTEM’ application for US clinical trial2014/08/12STEM CELL THERAPEUTIC
Lung disease stem cell drug designated ‘orphan drug in development stage’2014/07/29STEM CELL THERAPEUTIC
US patent for ‘CARTISTEM’ raw material stem cell differentiation capability selection technology2014/05/15STEM CELL THERAPEUTIC
Successful administration of stem cell dementia treatment drug ‘NEUROSTEM’2014/04/28STEM CELL THERAPEUTIC
Clinical thesis for lung treatment ‘PNEUMOSTEM’ published in international academic journal2014/02/10STEM CELL THERAPEUTIC
Football Manager Guus Hiddink, receives arthritis surgery with MEDIPOST’s stem cell technology2014/01/09STEM CELL THERAPEUTIC
Designated ‘Stem Cell Hair Growth Solution’ research institution by Ministry Commerce, Industry and Energy2013/12/20STEM CELL THERAPEUTIC
MEDIPOST Submits Application for Product Authorization Amendment to Add Ankle Indications for CARTISTEM®2023/12/27
MEDIPOST Selected for a Government-Supported R&D Project Worth KRW 13 billion, to be Used for Global Market Expansion Including the U.S.2023/10/04
MEDIPOST’s CARTISEM®, Umbilical Cord Blood-derived Stem Cell Transplant Surgery Clinical Study Results Published in SCI-Level Journal2023/05/02
MEDIPOST Treats First Subject with CARTISTEM® in Japan Phase 3 Clinical Trial, Accelerating Clinical Development efforts in Japan2023/01/16
MEDIPOST Enhances its Partnership with Canada’s OmniaBio in Collaboration for the CMDO Business of OmniaBio’s All-Around Cell and Gene Therapy.2022/12/01